StockGuide AI - assistant for portfolio management and market research

Analysts expect a potential turnaround for iShares U.S. Medical Devices ETF (IHI) amid improving technical indicators

06/10/2026, 06:36 PM investing forecast Analysts: analysts healthcare

The iShares U.S. Medical Devices ETF (IHI) is showing signs of a potential turnaround after a prolonged downtrend, which could present a favorable risk/reward scenario for investors. Recent technical indicators suggest that IHI may be poised for a rebound as it tests key support levels.

Traders Eye Cigna (CI) as a Stable Investment Amid Market Volatility

06/10/2026, 05:37 PM investing review healthcare

Cigna is being highlighted as a stable investment option amidst market volatility, with strong earnings and a significant buyback program making it attractive for income-focused investors.

Jim Cramer Maintains Position in Eli Lilly (LLY) Amid Strong Obesity Drug Pipeline

06/08/2026, 07:35 PM business review healthcare

Eli Lilly's stock continues to rise, driven by promising data on its obesity drug retatrutide, prompting analysts and investors to maintain their positions despite the stock's significant gains.

Zealand Pharma (ZEAL) Shares Plunge 23% Following Safety Concerns Over Survodutide Data

06/08/2026, 07:35 PM business stock_drop healthcare

Zealand Pharma's shares fell sharply by 22.7% following concerns over the safety profile of its weight loss drug survodutide, which showed a high dropout rate due to gastrointestinal side effects in a late-stage study. This decline highlights the challenges the company faces in a competitive market dominated by established players like Novo Nordisk and Eli Lilly.

Analysts expect Johnson & Johnson (JNJ) to show potential for breakout following Eli Lilly’s (LLY) recent all-time highs

06/08/2026, 06:35 PM investing forecast Analysts: analysts pharma healthcare

Pharmaceutical stocks are gaining momentum, with Eli Lilly leading the charge and reaching all-time highs, indicating a potential for broader sector strength that could benefit other major companies like Johnson & Johnson.

Novo Nordisk and Eli Lilly Compete for Dominance in the GLP-1 Pill Market Ahead of Medicare Coverage

06/08/2026, 05:48 PM business review healthcare

Novo Nordisk and Eli Lilly are intensifying their competition in the GLP-1 pill market as they prepare for Medicare coverage, which could significantly increase access to their obesity treatments. Both companies are focusing on marketing strategies to appeal to seniors, who will soon be able to access these medications at a reduced cost.

AstraZeneca CEO Pascal Soriot Highlights AI’s Role in Enhancing Drug Development Efficiency

06/05/2026, 10:33 PM growth healthcare

AstraZeneca's CEO Pascal Soriot highlighted the transformative role of artificial intelligence in accelerating drug development and enhancing decision-making processes, which could significantly improve the company's productivity and success rates in clinical trials.

Analysts Bank of America and Goldman Sachs recommend buying Nvidia (NVDA) and Sotera Health (SHC) respectively, while JPMorgan upgrades Tesla (TSLA) to neutral

06/05/2026, 12:34 PM investing review Analysts: analysts, Bank of America, Goldman Sachs, JPMorgan software healthcare

Recent analyst calls highlight significant shifts in ratings and price targets for various companies, indicating potential investment opportunities and risks for investors. Notably, firms like JPMorgan and Goldman Sachs are optimistic about companies like Qualcomm and Tesla, while others like BTIG and Berenberg express caution on Lululemon and CrowdStrike.

Dow Jones Industrial Average Hits Record High as Health-Care Stocks Lead Market Gains

06/05/2026, 12:34 PM business review healthcare

Despite a decline in chip stocks, the U.S. stock market saw significant gains, with the Dow Jones Industrial Average reaching a new record, driven largely by strong performance in the health-care sector.

Viatris (VTRS) Sees Revenue Growth and Pipeline Development Boosting Valuation Potential

06/04/2026, 06:31 PM investing growth healthcare

Viatris is experiencing a turnaround with improving sales and margins, driven by a strategic focus on drug development that could enhance its valuation and shareholder value. The company is poised for growth with a promising pipeline and cost-cutting measures that are already yielding positive results.

Topic: healthcare